***Sang-Min Jeon, Ph.D.***

***Associate Professor, CEO/CTO***

**EDUCATION**

Ph.D., 2011, Department of Biochemistry & Molecular Genetics, College of Medicine, University of Illinois at Chicago, IL – *Mentor: Nissim Hay, Ph.D.*

*Thesis title: The Role of Metabolic Pathways in Signal Transduction and Tumorigenesis*

M.S., 2001, College of Pharmacy, Seoul National University, Korea – *Mentor: Chang-Kiu Moon, Ph.D.*

B.S., 1999, College of Pharmacy, Seoul National University, Korea – *Mentor: Uhtaek Oh, Ph.D.*

**POSITIONS AND EMPLOYMENT**

2019.10 – Present CEO/CTO, SCL Therapeutics, Heungdeok IT Valley, Yongin, Korea

2013.09 – Present Assistant/Associate Professor, Lab of Integrative Cancer Signaling & Metabolism Network, College of Pharmacy, Ajou University, Suwon, Korea

2012.01 – 2013.07 Postdoctoral Research Fellow, Research Oncology, Genentech Inc., South San Francisco, CA – *PI: Georgia Hatzivassiliou, Ph.D.*

2011.05 – 2011.12 Postdoctoral Research Associate, Department of Biochemistry & Molecular Genetics, College of Medicine, University of Illinois at Chicago, IL – *PI: Nissim Hay, Ph.D.*

2001.03 – 2005.09 Technical Research Personnel, Center for Molecular Medicine, Samsung Biomedical Research Institute, Korea – *PI: Joobae Park, M.D./Ph.D.*

**SELECTED PUBLICATIONS**

1. Ju C*\**, **Jeon SM***\**, Jun HS, Moon CK. Diol-ginsenosides from Korean Red Ginseng delay the development of type 1 diabetes in diabetes-prone biobreeding rats. **J Ginseng Res*.*** *2019 June (online) (\* co-first author)*
2. Ham IH, Oh HJ, Jin H, Bae CA, **Jeon SM**, Choi KS, Son SY, Han SU, Brekken RA, Lee D, Hur H. Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer. **Mol Cancer**. *2019 Mar 30;18(1):68*.
3. Noh Y, **Jeon SM**, Shin S. Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy. **Int J Cancer**. *2019 Apr 1;144(7):1530-1539.*
4. **Jeon SM***\**, Hay N*\**. Expanding the concepts of cancer metabolism. **Exp Mol Med**. *2018 Apr 16;50(4):32. (\* co-corresponding author)*
5. **Jeon SM***\**, Shin AE. Exploring vitamin D metabolism and function in cancer. **Exp Mol Med**. *2018 Apr 16;50(4):20. (\* corresponding author)*
6. Kim S, Lee E, Jung J, Lee JW, Kim HJ, Kim J, Yoo JH, Lee HJ, Chae SY, **Jeon SM**, Son BH, Gong GY, Sharan S, Chang S. microRNA-155 positively regulates glucose metabolism via PIK3R1-FOXO3a-cMYC axis in breast cancer. **Oncogene.** *2018 Mar 12.*
7. Kim SR, Song JH, Ahn JH, Lee GS, Ahn H, Yoon SI, Kang SG, Kim PH, **Jeon SM**, Choi EJ, Shin S, Cha Y, Cho S, Kim DE, Chang SY, Ko HJ. Antiviral and anti-inflammatory activity of budesonide against human rhinovirus infection mediated via autophagy activation. **Antiviral Res.** *2018 Feb 1;151:87-96.*
8. DeWaal D, Nogueira V, Terry AR, Patra KC, **Jeon SM**, Guzman G, Au J, Long CP, Antoniewicz MR, Hay N. Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin. **Nat Commun.** *2018 Jan 31;9(1):446.*
9. Jung BJ, Yoo HS, Shin S, Park YJ, **Jeon SM**. Dysregulation of NRF2 in Cancer: from Molecular Mechanisms to Therapeutic Opportunities. **Biomol Ther (Seoul).** *2018 Jan 1;26(1):57-68*
10. Choi EJ, Jung BJ, Lee SH, Yoo HS, Shin EA, Ko HJ, Chang S, Kim SY, **Jeon SM**. A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer. **Oncogene.** *2017 Sep 14;36(37):5285-5295.*
11. Hong EH, Heo EY, Song HJ, Kwon BE, Lee JY, Park Y, Kim J, Chang SY, Chin YW, **Jeon SM**\*, Ko HJ\*. Trans-scirpusin A showed antitumor effects via autophagy activation and apoptosis induction of colorectal cancer cells. **Oncotarget**. *2017, April 24. (\* co-corresponding author)*
12. Kim N, Yim HY, He N, Lee CJ, Kim JH, Choi JS, Lee HS, Kim S, Jeong E, Song M, **Jeon SM**, Kim WY, Mills GB, Cho YY, Yoon S. Cardiac glycosides display selective efficacy for STK11 mutant lung cancer. **Sci Rep**. *2016 Jul 19;6:29721.*
13. **Jeon SM**. Regulation and Function of AMPK in Physiology and Diseases. **Exp Mol Med**. *2016 Jul 15;48(7):e245.*
14. Kwon BE, Song JH, Song HH, Kang JW, Hwang SN, Rhee KJ, Shim A, Hong EH, Kim YJ, **Jeon SM**, Chang SY, Kim DE, Cho S, Ko HJ. Antiviral activity of oroxylin A against Coxsackievirus B3 alleviates virus-induced acute pancreatic damage in mice. **Plos One**. *2016 May 19;11(5):e0155784*
15. Wang Q, Yu WN, Chen X, Peng XD, **Jeon SM**, Birnbaum M, Guzman G, Hay N. Spontaneous Hepatocellular Carcinoma after the Combined Deletion of Akt Isoforms. **Cancer Cell**. *2016, Apr 11; 29(4):523-535.*
16. **Jeon SM**\*, Hay N. The double-edged sword of AMPK signaling in cancer and its therapeutic implications. **Arch Pharm Res**. *2015 Mar 1;38(3):346-57. (\* corresponding author)*
17. **Jeon SM**\*, Hay N. The dark face of AMPK as an essential tumor promoter. **Cell Logist**. *2012 Oct 1;2(4):197-202.* (\* corresponding author)
18. **Jeon SM**, Chandel N, Hay N. AMPK regulates NADPH homeostasis to promote tumor cell survival during energy stress. **Nature**. *2012 May 31; 485, 661–665.*
19. Xu PZ, Chen ML, **Jeon SM**, Peng XD, Hay N. The effect of Akt2 deletion on tumor development in Pten+/- mice. **Oncogene**. *2012 Jan 26;31(4):518-26.*
20. Chen CC, **Jeon SM**, Bhaskar PT, Nogueira V, Sundararajan D, Tonic I, Park Y, Hay N. FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor. **Dev Cell**. *2010 Apr 20;18(4):592-604.*
21. Bhaskar PT, Nogueira V, Patra KC, **Jeon SM**, Park Y, Robey RB, Hay N. mTORC1 hyperactivity inhibits serum deprivation apoptosis via increased HKII and GLUT1 expression, sustained Mcl-1 expression, and GSK3b inhibition. **Mol Cell Biol**. *2009 Sep;29(18):5136-47.*
22. Chen WS, Peng XD, Wang Y, Xu PZ, Chen ML, Luo Y, **Jeon SM**, Coleman K, Haschek WM, Bass J, Philipson LH, Hay N. Leptin deficiency and beta-cell dysfunction underlie type 2 diabetes in compound Akt knockout mice. **Mol Cell Biol**. *2009 Jun;29(11):3151-62.*
23. **Jeon SM**, Choi B, Hong KU, Kim E, Seong YS, Bae CD, Park J. A cytoskeleton-associated protein, TMAP/CKAP2 is involved in the proliferation of human foreskin fibroblasts. **Biochem. Biophys. Res. Commun**. *2006 Sep 15; 348:222-228.*

**PATENTS**

1. KR patent pending 2019-0035841, A pharmaceutical composition for the treatment of non-small cell lung cancer comprising a glucocorticoid compound, Ajou University Industry-Academia Cooperation Foundation, 2019. Mar. 28.
2. KR patent pending 2019-0035840, A pharmaceutical composition for the treatment of non-small cell lung cancer comprising a glucocorticoid compound, Ajou University Industry-Academia Cooperation Foundation, 2019. Mar. 28.
3. KR patent 1978629, A pharmaceutical composition for the treatment of non-small cell lung cancer comprising a glucocorticoid compound, Ajou University Industry-Academia Cooperation Foundation, 2018. Aug. 22.
4. CN patent pending 2016-80064090.8, Pharmaceutical composition for treating lung cancer comprising glucocorticoids, Ajou University Industry-Academic Cooperation Foundation, 2018. May. 02.
5. US patent pending 15/772714, Pharmaceutical composition for treating lung cancer comprising glucocorticoids, Ajou University Industry-Academic Cooperation Foundation, 2018. May. 01.
6. KR patent 1892908, A pharmaceutical composition for the treatment of non-small cell lung cancer comprising a glucocorticoid compound, Ajou University Industry-Academia Cooperation Foundation, 2016. Oct. 18.

**TECHNOLOGY TRANSFER: SCL Therapeutics 2019 June**

1. KR patent pending 2019-0035841, A pharmaceutical composition for the treatment of non-small cell lung cancer comprising a glucocorticoid compound, Ajou University Industry-Academia Cooperation Foundation, 2019. Mar. 28.
2. KR patent pending 2019-0035840, A pharmaceutical composition for the treatment of non-small cell lung cancer comprising a glucocorticoid compound, Ajou University Industry-Academia Cooperation Foundation, 2019. Mar. 28.
3. KR patent 1978629, A pharmaceutical composition for the treatment of non-small cell lung cancer comprising a glucocorticoid compound, Ajou University Industry-Academia Cooperation Foundation, 2018. Aug. 22.
4. CN patent pending 2016-80064090.8, Pharmaceutical composition for treating lung cancer comprising glucocorticoids, Ajou University Industry-Academic Cooperation Foundation, 2018. May. 02.
5. US patent pending 15/772714, Pharmaceutical composition for treating lung cancer comprising glucocorticoids, Ajou University Industry-Academic Cooperation Foundation, 2018. May. 01.
6. KR patent 1892908, A pharmaceutical composition for the treatment of non-small cell lung cancer comprising a glucocorticoid compound, Ajou University Industry-Academia Cooperation Foundation, 2016. Oct. 18.